On the Radar…

AmideBio, LLC announced that it has closed a round of seed funding. The source and the amount of funding were not disclosed by the company. The proceeds of the round will be used to complete initial product optimization using its recombinant hydrid manufacturing technology. AmideBio has an exclusive license, announced two week ago, with CU to commercialize a method to manufacture recombinant proteins and peptides developed by Associate Professor Michael Stowell, who also serves as the Chief Scientific Officer for AmideBio. The new manufacturing technique has the potential both to reduce costs and to make it feasible to manufacture drugs that were difficult to produce with conventional methods. AmideBio is based in Boulder, Colorado.